Inflammatory myopathy

G6_INFLAMYOP

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — G72.4 Cause of death: ICD-10 — G72.4 2 out of 7 registries used, show all original rules.	51
4. Check minimum number of events None	51
5. Include endpoints None	51
6. Filter based on genotype QC (FinnGen only)	51

Control definitions (FinnGen only)

Control exclude: G6_MYONEU

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: G72
Name in latin: Myopathia inflammatoria non alibi classificata

NAME	G6_INFLAMYOP
CONTROL_EXCLUDE	G6_MYONEU
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	G724
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	G724
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Inflammatory myopathy based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	383	177	205
Only index persons	356	166	190
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	72.29	72.78	71.86
Only index persons	72.51	73.14	71.96

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	51	24	27
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	74.53	73.46	75.48

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(4035726)

6.51

9.12

1.4

1.2

—

(3022313) Gas panel - Capillary blood

11.06

8.37

3.5

8.5

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

8.49

7.47

1.7

—

(3019225) pH of Specimen

6.02

7.31

3.8

5.3

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

7.52

6.74

1.7

2.0

—

(43055089) Myosin Ab [Presence] in Serum or Plasma by Immunoblot

+∞

6.37

1.3

0.0

—

(42529598) SUMO-activating enzyme subunit 1 Ab [Presence] in Serum by Line blot

+∞

5.29

1.4

0.0

—

(42528593) TIF1-gamma Ab [Presence] in Serum by Line blot

+∞

5.29

1.4

0.0

—

(42529582) MDA5 Ab [Presence] in Serum by Line blot

+∞

5.29

1.4

0.0

—

(3013637) Mi-2 Ab [Presence] in Serum

+∞

5.29

1.4

0.0

—

(3013512) EKG study

119

3.70

5.02

5.0

5.1

—

(3019198) Lymphocytes [#/volume] in Blood

198

3.78

4.65

8.1

5.5

1.8

1.7

e9/l

0.59

173

(3013115) Eosinophils [#/volume] in Blood

201

3.69

4.48

9.3

5.6

0.1

0.2

e9/l

1.11

175

(42870588) Differential panel, method unspecified - Blood

136

3.35

4.32

10.8

5.4

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

4.73

3.90

1.9

1.4

—

(3032080) INR in Blood by Coagulation assay

168

2.91

3.39

12.9

6.3

1.3

1.2

inr

—

(3019309) Folate [Moles/volume] in Red Blood Cells

105

2.93

3.32

2.7

1.7

1255.2

1263.4

nmol/l

0.01

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

3.14

3.31

2.3

1.9

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

8.30

3.14

2.2

1.3

—

(3007853) Bacteria identified in Skin by Aerobe culture

3.29

2.99

1.7

1.6

—

(3009445) Proteinase 3 Ab [Units/volume] in Serum

5.06

2.93

1.5

1.2

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

105

2.70

2.84

2.0

1.7

377.1

450.5

pmol/l

0.81

(3023368) Bacteria identified in Blood by Culture

127

2.48

2.49

5.9

4.5

—

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

104

2.52

2.44

2.7

1.9

2.6

2.8

mg/l

0.29

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

210

2.41

2.31

10.2

8.5

1.2

mmol/l

0.08

175

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

5.40

2.12

1.0

1.4

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

200

2.21

1.99

10.8

7.4

1.2

mmol/l

0.05

170

(3042936) Bacteria identified in Isolate by Culture

2.60

1.91

4.4

2.1

—

(3037467) Urinalysis macro (dipstick) panel - Urine

283

2.34

1.87

6.2

4.9

—

(3049804) Myeloperoxidase IgG Ab [Units/volume] in Serum

3.84

1.65

1.8

1.1

—

(40768804) Tissue Pathology biopsy report

157

2.00

1.57

2.1

2.0

—

(3013707) Erythrocyte sedimentation rate by Westergren method

295

2.13

1.51

7.5

4.1

20.7

14.2

mm/h

1.13

257

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

2.73

1.51

2.0

2.1

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

152

1.93

1.44

3.0

3.2

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

2.38

1.42

1.9

1.5

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

2.82

1.41

1.3

1.9

—

(40760892) CBC W Ordered Manual Differential panel - Blood

2.06

1.33

4.5

5.0

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

192

1.86

1.33

2.7

2.6

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

2.58

1.28

1.5

2.0

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

105

1.93

1.27

2.5

3.0

—

(40768797) Stomach Pathology biopsy report

2.20

1.21

1.1

1.4

—

(3027273) Bicarbonate [Moles/volume] in Venous blood

2.66

1.18

1.8

4.8

25.6

24.1

mmol/l

—

(36304419) Bacteria [Presence] in Urine

116

1.85

1.17

2.9

—

(3002256) Pathology report gross observation

2.11

1.09

1.1

1.2

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

2.06

1.05

1.8

1.9

—

(3004588) Protein electrophoresis panel - Serum or Plasma

2.16

1.04

1.3

2.5

—

(3003338) MCHC [Mass/volume]

305

0.60

0.97

38.0

22.0

328.6

331.8

g/l

1.00

305

(3011397) Hemoglobin [Presence] in Urine by Test strip

0.47

0.89

2.0

3.8

—

(3022621) pH of Urine by Test strip

1.99

0.85

4.2

2.6

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.79

0.83

6.6

3.4

—

(3009508) Creatinine [Moles/volume] in Urine

128

1.63

0.80

2.6

3.3

7.7

7.1

mmol/l

—

102

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

175

1.57

0.78

2.3

2.0

93.9

83.9

pmol/l

0.52

(3036481) Cortisol [Moles/volume] in Serum or Plasma

1.97

0.77

3.7

1.7

274.6

408.3

nmol/l

—

(3012516) Albumin [Mass/volume] in Urine

121

1.61

0.75

2.6

3.3

118.9

585.3

mg/l

—

(3002385) Erythrocyte distribution width [Ratio]

312

0.66

0.69

38.3

20.1

14.7

13.8

1.51

306

(40761511) CBC panel - Blood by Automated count

397

1.79

0.68

34.4

15.3

—

(3020682) Albumin/Creatinine [Ratio] in Urine

133

1.55

0.67

3.7

4.2

20.8

7.1

mg/mmol

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.75

0.66

2.0

1.6

—

(3041096) Erythrocytes [Presence] in Urine by Automated

116

1.55

0.65

4.8

4.1

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

1.74

0.63

2.6

1.5

—

(3025941) Bacteria identified in Stool by Culture

0.00

0.61

0.0

1.4

—

(40761536) Microorganisms panel - Urine sediment

1.86

0.61

4.8

—

(3022145) Colonoscopy Study observation

1.81

0.60

1.2

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

0.00

0.60

0.0

1.3

—

(3003694) ABO and Rh group [Type] in Blood

0.57

0.59

1.7

1.4

—

(3020564) Creatinine [Moles/volume] in Serum or Plasma

411

1.80

0.59

29.4

19.6

71.0

84.0

umol/l

0.77

411

(3019060) Gas panel - Arterial blood

1.70

0.58

15.8

3.9

—

(3026008) Bacteria identified in Urine by Culture

147

1.47

0.56

3.4

3.5

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

370

1.55

0.53

4.8

4.9

4.3

4.5

mmol/l

0.47

328

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

370

1.55

0.53

23.5

16.3

89.7

74.9

ml/min/173m2

2.59

285

(3021447) Carbon dioxide [Partial pressure] in Venous blood

1.64

0.51

2.1

5.9

6.8

5.8

kpa

—

(3044640) Blood type and Crossmatch panel - Blood

140

1.44

0.51

2.7

2.8

—

(3012544) pH of Venous blood

1.60

0.51

2.3

5.8

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.53

0.49

2.9

1.9

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.50

0.48

2.9

1.9

—

(3044889) 12 lead EKG panel

281

0.72

0.47

5.0

4.1

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

352

1.46

0.46

4.9

4.3

1.4

1.2

mmol/l

1.11

303

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

363

1.47

0.46

5.1

4.7

1.9

2.0

mu/l

0.28

310

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.68

0.44

1.6

1.3

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.00

0.42

0.0

1.5

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

1.43

0.39

1.2

1.7

—

(3007164) IgA [Mass/volume] in Serum or Plasma

1.44

0.38

2.0

1.5

3.2

2.2

g/l

—

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

368

1.40

0.37

5.2

4.8

1.4

1.5

mmol/l

0.58

319

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.43

0.33

16.1

8.9

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

382

1.37

0.31

6.2

5.2

6.0

6.1

mmol/l

0.03

330

(40758558) Short blood count panel - Blood

107

1.29

0.25

9.6

6.4

—

(3035350) Ketones [Presence] in Urine by Test strip

204

1.23

0.24

3.8

4.2

0.0

estimate

—

(1761868) Lipid panel - Serum or Plasma

102

0.74

0.24

2.5

3.4

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

387

1.30

0.23

5.3

5.5

2.5

2.6

mmol/l

0.16

335

(3024354) Oxygen [Partial pressure] in Venous blood

1.31

0.23

2.6

3.8

5.7

3.9

kpa

—

(3000991) Gas panel - Venous blood

1.28

0.23

5.8

13.2

—

(3015736) pH of Urine

156

1.24

0.23

3.6

4.1

—

(3009261) Glucose [Presence] in Urine by Test strip

205

1.22

0.22

4.6

4.2

0.0

estimate

—

(1002224) Polysomnography panel

0.00

0.21

0.0

1.1

—

(3003181) Sodium [Moles/volume] in Urine

0.00

0.21

0.0

1.6

—

66.8

—

(3001019) Free T4 and TSH panel - Serum or Plasma

0.00

0.21

0.0

1.1

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

0.00

0.21

0.0

1.2

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

0.00

0.21

0.0

1.3

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

0.21

0.0

1.3

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.21

0.0

3.1

—

(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum

0.00

0.20

0.0

1.1

—

(3021601) Nitrite [Presence] in Urine by Test strip

202

1.16

0.13

5.9

5.8

0.0

estimate

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

157

0.85

0.13

5.9

5.7

2.2

2.4

ug/l

0.14

136

(3009542) Hematocrit [Volume Fraction] of Blood

333

1.16

0.13

29.7

18.3

32.2

39.3

1.05

212

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

193

1.15

0.12

7.0

4.3

—

(3000494) Fungus identified in Specimen by Culture

1.15

0.09

4.7

1.5

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

122

0.87

0.08

4.3

5.1

25.1

23.1

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

158

1.11

0.07

5.3

4.6

—

(3029937) Albumin [Presence] in Urine by Test strip

117

1.03

0.00

3.5

4.4

0.0

estimate

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

0.0

1.2

—

(40760847) Basement membrane Ab [Titer] in Serum by Immunofluorescence

0.00

0.0

1.3

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

0.00

0.0

1.4

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

4.2

—

127.0

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.0

1.2

—

(3035637) Corticotropin [Mass/volume] in Plasma

0.00

0.0

1.4

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

0.0

1.1

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.0

1.1

—

(3005033) Fetal Nuchal fold Thickness US

0.00

0.0

1.2

—

(42870365) C reactive protein [Mass/volume] in Blood by High sensitivity method

0.00

0.0

1.2

—

(3027544) Mycobacterium sp identified in Sputum by Organism specific culture

0.00

0.0

3.7

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

0.0

1.8

—

(3020059) Calcium [Moles/volume] corrected for albumin in Serum or Plasma

0.89

0.00

2.9

2.8

2.5

mmol/l

—

(3051593) INR in Capillary blood by Coagulation assay

0.00

0.0

13.0

—

(21494890) Protein electrophoresis panel - 24 hour Urine

0.00

0.0

1.2

—

(42870308) Desmosome IgG Ab [Titer] in Serum by Immunofluorescence

0.00

0.0

1.3

—

(40768795) Lymph node Pathology biopsy report

0.00

0.0

1.1

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.0

4.8

—

19.4

—

(42529406) Shigella sp [Presence] in Stool by Culture

0.00

0.0

1.1

—

(3006418) Campylobacter sp identified in Tissue by Organism specific culture

0.00

0.0

1.1

—

(3020491) Glucose [Moles/volume] in Blood

0.00

0.0

1.4

—

7.0

—

(3009595) Pneumocystis jiroveci DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

1.0

—

(21494434) Karyotype in Bone marrow

0.00

0.0

1.0

—

(40768793) Breast Pathology biopsy report

0.00

0.0

1.1

—

(3019230) Fractional oxyhemoglobin in Venous blood

0.00

0.0

3.4

—

53.7

—

(42868544) Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence

0.00

0.0

1.0

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.0

1.1

—

(3028531) Enolase.neuron specific [Mass/volume] in Serum or Plasma

0.00

0.0

2.1

—

14.5

—

(3019601) Blood group antibody investigation [Interpretation] in Plasma or RBC

0.00

0.0

1.4

—

(3000034) Microalbumin [Mass/volume] in Urine

0.00

0.0

4.3

—

42.0

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.0

1.3

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

0.0

4.5

—

4.5

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

0.0

1.2

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

0.00

0.0

1.1

—

(3014765) Yersinia sp identified in Stool by Organism specific culture

0.00

0.0

1.1

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

0.0

1.2

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

0.0

1.2

—

(3008898) HLA-B27 [Presence]

0.00

0.0

1.1

—

Mortality – FinRegistry

↥

Association

Association between endpoint G6_INFLAMYOP and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have G6_INFLAMYOP.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: G6_INFLAMYOP – Inflammatory myopathy

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Inflammatory myopathy

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints